---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000004"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:58:38.307113+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna reports prelim 2022 COVID sales $18.4B; reiterates 2023 $5B min; RSV study accrues cases

## Summary
- Prelim 2022 COVID vaccine sales ~$18.4B; R&D ~$3.3B; cash & investments >$18B.
- 2023 min COVID sales reiterated at ~$5B; R&D budget rises to ~$4.5B.
- RSV vaccine (mRNA-1345) Phase 3 in older adults accrued enough cases for first interim efficacy analysis.
- Personalized cancer vaccine mRNA-4157 + Keytruda reduced recurrence risk by 44% in melanoma; Phase 3 to start 2023.
- Repurchased 23M shares for $3.3B in 2022; $2.8B remaining; acquired OriCiro Genomics.

## SEC filing metadata
- accession: 0001682852-23-000004
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/0001682852-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/mrna-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000004
- JSON: https://secwatch.observer/filing/0001682852-23-000004.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000004.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported the fiscal year ended December 31, 2022 results: revenue approximately $18.4 billion.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: approximately $18.4 billion
  - Result: preliminary results
  source text: COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/0001682852-23-000004-index.htm
- Earnings Releases
  Moderna, Inc. reported 2023 results: revenue approximately $5.0 billion. Guidance reaffirmed.
  - Period: 2023
  - Revenue: approximately $5.0 billion
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Reiterating 2023 expected minimum COVID-19 vaccines sales of approximately $5.0 billion from confirmed Advance Purchase Agreements and 2022 contract deferrals
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/0001682852-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.